Upregulation of TMEM45A Promoted the Progression of Clear Cell Renal Cell Carcinoma in vitro

References

• Linehan WM, Ricketts CJ. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019;16(9):539–552. doi:10.1038/s41585-019-0211-5
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Gray RE, Harris GT. Renal cell carcinoma: diagnosis and management. Am Fam Physician. 2019;99(3):179–184.
   PubMed Web of Science ®Google Scholar
• Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79–87. doi:10.14740/wjon1279
   PubMedGoogle Scholar
• Pontes O, Oliveira-Pinto S, Baltazar F, Costa M. Renal cell carcinoma therapy: current and new drug candidates. Drug Discov Today. 2021. doi:10.1016/j.drudis.2021.07.009
   PubMed Web of Science ®Google Scholar
• Tacconi EMC, Tuthill M, Protheroe A. Review of adjuvant therapies in renal cell carcinoma: evidence to date. Onco Targets Ther. 2020;13:12301–12316. doi:10.2147/OTT.S174149
   PubMed Web of Science ®Google Scholar
• Schmit K, Michiels C. TMEM proteins in cancer: a review. Front Pharmacol. 2018;9:1345. doi:10.3389/fphar.2018.01345
   PubMed Web of Science ®Google Scholar
• Sun W, Qiu G, Zou Y, et al. Knockdown of TMEM45A inhibits the proliferation, migration and invasion of glioma cells. Int J Clin Exp Pathol. 2015;8(10):12657–12667.
   PubMed Web of Science ®Google Scholar
• Flamant L, Roegiers E, Pierre M, et al. TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. BMC Cancer. 2012;12:391. doi:10.1186/1471-2407-12-391
   PubMed Web of Science ®Google Scholar
• Thibodeau BJ, Fulton M, Fortier LE, et al. Characterization of clear cell renal cell carcinoma by gene expression profiling. Urol Oncol. 2016;34(4):168.e161–169. doi:10.1016/j.urolonc.2015.11.001
   PubMed Web of Science ®Google Scholar
• Wrzesiński T, Szelag M, Cieślikowski WA, et al. Expression of pre-selected TMEMs with predicted ER localization as potential classifiers of ccRCC tumors. BMC Cancer. 2015;15:518. doi:10.1186/s12885-015-1530-4
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–678. doi:10.1038/s41587-020-0546-8
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–w560. doi:10.1093/nar/gkz430
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1–6. doi:10.1016/S1476-5586(04)80047-2
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474. doi:10.1245/s10434-010-0985-4
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18(2):128–134. doi:10.1038/nrc.2017.118
   PubMed Web of Science ®Google Scholar
• Lee CH. Epithelial-mesenchymal transition: initiation by cues from chronic inflammatory tumor microenvironment and termination by anti-inflammatory compounds and specialized pro-resolving lipids. Biochem Pharmacol. 2018;158:261–273. doi:10.1016/j.bcp.2018.10.031
   PubMed Web of Science ®Google Scholar
• Sistigu A, Di Modugno F, Manic G, Nisticò P. Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. Cytokine Growth Factor Rev. 2017;36:67–77. doi:10.1016/j.cytogfr.2017.05.008
   PubMed Web of Science ®Google Scholar
• López-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med. 2009;1(6–7):303–314. doi:10.1002/emmm.200900043
   PubMed Web of Science ®Google Scholar
• Lee S, Stewart S, Nagtegaal I, et al. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res. 2012;72(17):4574–4586. doi:10.1158/0008-5472.CAN-12-0636
   PubMed Web of Science ®Google Scholar
• Guo J, Chen L, Luo N, Yang W, Qu X, Cheng Z. Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells. Oncol Rep. 2015;33(6):3124–3130. doi:10.3892/or.2015.3902
   PubMed Web of Science ®Google Scholar
• Piva F, Giulietti M, Santoni M, et al. Epithelial to mesenchymal transition in renal cell carcinoma: implications for cancer therapy. Mol Diagn Ther. 2016;20(2):111–117. doi:10.1007/s40291-016-0192-5
   PubMed Web of Science ®Google Scholar
• Wang P, Chen W, Ma T, et al. lncRNA lnc-TSI inhibits metastasis of clear cell renal cell carcinoma by suppressing TGF-β-induced epithelial-mesenchymal transition. Mol Ther Nucleic Acids. 2020;22:1–16. doi:10.1016/j.omtn.2020.08.003
   PubMedGoogle Scholar
• Liu Y, Liu L, Mou ZX. TMEM45A affects proliferation, apoptosis, epithelial-mesenchymal transition, migration, invasion and cisplatin resistance of HPV-positive cervical cancer cell lines. Biochem Genet. 2021. doi:10.1007/s10528-021-10094-3
   Web of Science ®Google Scholar
• Zhu M, Jiang B, Yan D, Wang X, Ge H, Sun Y. Knockdown of TMEM45A overcomes multidrug resistance and epithelial-mesenchymal transition in human colorectal cancer cells through inhibition of TGF-β signalling pathway. Clin Exp Pharmacol Physiol. 2020;47(3):503–516. doi:10.1111/1440-1681.13220
   PubMed Web of Science ®Google Scholar
• Vincent CT, Fuxe J. EMT, inflammation and metastasis. Semin Cancer Biol. 2017;47:168–169. doi:10.1016/j.semcancer.2017.09.003
   PubMed Web of Science ®Google Scholar
• Suarez-Carmona M, Lesage J, Cataldo D, Gilles C. EMT and inflammation: inseparable actors of cancer progression. Mol Oncol. 2017;11(7):805–823. doi:10.1002/1878-0261.12095
   PubMed Web of Science ®Google Scholar
• Verma A, Somvanshi P, Haque S, Rathi B, Sharda S. Association of inflammatory bowel disease with arthritis: evidence from in silico gene expression patterns and network topological analysis. Interdiscip Sci. 2019;11(3):387–396. doi:10.1007/s12539-017-0272-1
   PubMed Web of Science ®Google Scholar